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Coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome 
coronavirus-2 (SARS-CoV-2) is causing a dramatic pandemic.1 Lombardy, in northern 
Italy, is one of the regions most affected worldwide.2 Cardiovascular complications occur 
frequently in COVID-19 patients,3 with challenges in the acute management. We aimed 
to evaluate incidence, clinical presentation, angiographic findings, and clinical outcomes 
of ST-elevation myocardial infarction (STEMI) in COVID-19 patients. 
All hospitals with catherization laboratories in Lombardy were contacted to 
collect cases of patients with confirmed COVID-19 whom underwent an urgent coronary 
angiogram due to STEMI between February 20 (date of first COVID-19 case in 
Lombardy) and March 30, 2020.2 Data were collected retrospectively, in anonymized 
fashion without any sensitive data, therefore not requiring institutional review board 
approval. COVID-19 was confirmed a reverse transcription–polymerase chain reaction 
assays. STEMI was defined based on the presence of typical symptoms associated with 
ST-segment elevation or new left bundle branch block (LBBB).4 A stenosis was 
considered as culprit lesion in case of angiographic evidence of thrombotic 
occlusion/subocclusion. Obstructive coronary artery disease was defined based on the 
angiographic evidence of a stenosis >50% on visual estimation.  
A total of 28 COVID-19 patients with STEMI were included. All patients met 
guideline-definition of STEMI4 with localized ST-elevation (25 patients, 89.3%) or new 
LBBB (3 patients, 10.7%), and were all treated in the setting of emergent activation.  
The Table displays a detailed overview of each included patient. The mean age 
was 68±11 years, 8 patients (28.6%) were women, 20 (71.4%) had arterial hypertension, 
9 (32.1%) had diabetes mellitus, 8 (28.6%) had chronic kidney disease, and 3 (10.7%) 
had a prior myocardial infarction.  
For 24 patients (85.7%) the STEMI represented the first clinical manifestation of 
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COVID-19, and did not have a COVID-19 test result at the time of coronary angiography. 
The remaining 4 patients suffered from STEMI during hospitalization for COVID-19. 
Twenty-two patients (78.6%) presented with typical chest pain associated or not with 
dyspnea, 6 patients (21.4%) had dyspnea without chest pain.  
On echocardiography, 23 patients (82.1%) had localized wall motion 
abnormalities, 3 (10.7%) had diffuse hypokinesia, and 2 (7.1%) did not have 
abnormalities. The left ventricular ejection fraction was <50% in 17 patients (60.7%). 
All patients underwent urgent coronary angiography and none was treated with 
fibrinolysis. Out of 28 patients, 17 patients (60.7%) had evidence of a culprit lesion 
requiring revascularization and 11 patients (39.3%) did not have obstructive coronary 
artery disease.  
As of March 31, 2020 (median follow-up 13 days, interquartile range 2-20 days), 
11 patients (39.3%) died, 1 (3.6%) was still hospitalized in intensive care unit, and 16 
(57.1%) had been discharged.  
During the COVID-19 outbreak the regional STEMI-network was reorganized2 
and we have been observing a reduction in the number patients presenting with STEMI. 
Both factors might have contributed to the relative low number of cases observed during 
the study period. However, considering the cardiovascular risk profile of COVID-19 
patients, many of these are expected to suffer from STEMI in the upcoming months. 
Evidence-based strategies are mandatory to guide their clinical management. Our 
findings provide relevant evidence showing that, while all patients had a typical STEMI 
presentation, angiography demonstrated the absence of a culprit lesion in 39.3% of cases, 
therefore excluding a type 1 myocardial infarction.  
A recent document from the American College of Cardiology’s Interventional 
Council and the Society of Cardiovascular Angiography and Intervention discusses how 
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to guarantee state-of-the-art treatment as well as safety of healthcare providers involved 
in management of STEMI in the context of a COVID-19 outbreak.3 The document 
recommends to weight carefully the balance between healthcare providers exposure and 
patient benefit. Our findings underscore that all efforts should be made to differentiate 
between type 2 myocardial infarctions and myocarditis versus type 1 myocardial 
infarctions.  
Our findings also show that a strategy relying on systematic fibrinolysis5 is not 
justified, since reperfusion appears not to be required in a significant proportion of 
COVID-19 patients with STEMI.  
We acknowledge that this is an early report on a relatively small number of 
patients. However, we wish to underscore to have systematically collected COVID-19 
patients with STEMI in Lombardy during the first 6 weeks of outbreak.  
In patients in whom a culprit lesion was excluded by coronary angiography we 
were unable to determine whether the clinical presentation was due to a type 2 myocardial 
infarction, to a myocarditis subsequent to SARS-CoV-2 infection, to SARS-CoV-2-
related endothelial dysfunction, or to a cytokine storm. Further investigations are needed 
to fully elucidate the pathophysiology of myocardial injury in COVID-19 patients. 
In conclusion, our findings show that STEMI may represent the first clinical 
manifestation of COVID-19. In approximately 40% of COVID-19 patients with STEMI, 
a culprit lesion is not identifiable by coronary angiography. A dedicated diagnostic 
pathway should be delineated for COVID-19 patients with STEMI, aimed at minimizing 
patients procedural risks and healthcare providers risk of infection. 
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Table. Overview of included patients. 
N Age, y Sex BMI, Kg/m
2 
Cardiovascular risk factors Medical history Clinical presentation EKG 
changes 
LVE
F, % WMA 
Culprit 
vessel Stenosis 
Clinical 
status* HTN Dyslip DM CKD Active smoke Prior PCI 
Prior 
CABG 
Prior 
MI 
Symptoms Hemodynamic parameters 
Chest pain Dyspnea NYHA SBP, mmHg HR, bpm O2 sat, % 
Patients without a culprit lesion 
1 79 F 30.2 Y N N N N Y N N N Y II 145 90 95 ST-elevation, inferior 58 13,14,15,16, 17 - - Discharged 
2 66 F 22.7 Y N N N N N N N Y Y III 165 90 97 ST-elevation, inferior 39 4,9,10,14,15,17 - - Discharged 
3 64 F 24.4 Y N N N N N N N Y N I 160 114 92 ST-elevation, anterolateral 35 13,14,15,16, 17 - - Discharged 
4 77 M 24.6 Y N Y Y N N N N Y Y III 145 66 96 ST-elevation, lateral 60 None - - Death 
5 89 M 27.4 Y N N Y N N N N Y N II 140 92 89 ST-elevation, anterolateral 35 7,13,17 - - Death 
6 53 F 19.9 N N N Y N N N N N Y III 110 98 92 ST-elevation, inferolateral 26 Diffuse - - Discharged 
7 69 M 24.5 Y Y N Y N N N N N Y IV 70 110 90 new LBBB 30 1,7,13 - - Death 
8 54 F 23.4 N N N N N N N N Y Y IV 110 60 96 new LBBB 60 None - - Discharged 
9 71 M 22.2 Y Y N N N N N N Y Y II 130 80 96 ST-elevation, inferior 35 3,4,5,10,11 - - Discharged 
10 65 M 27.6 Y N N N Y N N Y N Y IV 70 118 88 ST-elevation, inferior 55 4,10 - - Death 
11 75 M 23.7 Y Y N Y N N N N Y Y II 140 90 90 ST-elevation, inferolateral 40 Diffuse - - Death 
Patients with a culprit lesion 
12 79 M 24.2 N N N Y N N N N Y Y IV 80 95 96 ST-elevation, anterolateral 10 6,12,16,17 LM 
100%, 
thrombotic Death 
13 74 M 24.8 Y Y Y N N Y N Y Y Y III 150 115 90 ST-elevation, anterior 25 1,7,13 
ostial 
LAD 
100%, 
thrombotic Death 
14 66 M 22.9 N N Y N N N N N Y Y IV 90 99 91 ST-elevation, anterolateral 26 7,8 prox LAD 
100%, 
thrombotic Discharged 
15 59 M 27.7 Y Y Y Y N N N N Y Y IV 120 105 88 ST-elevation, anterior 35 8,12 prox LAD 
90%, 
thrombotic Death 
16 45 F 27.5 N N N N N N N N Y Y II 120 115 98 ST-elevation, anterior 50 7,8,13,14 mid LAD 
100%, 
thrombotic Discharged 
17 83 M 30.0 Y Y N N N N N N N Y III 160 65 95 new LBBB 48 2,8,14,17 mid LAD 90%, thrombotic Discharged 
18 63 M 22.6 Y N Y N N N N N Y N I 150 82 98 ST-elevation, anterior 51 13,14,17 mid LAD 
99%, 
thrombotic Discharged 
19 49 M 23.5 N N N N Y N N N Y N II 113 66 98 ST-elevation, inferior 55 3,4,5,10,11 prox LCX 
99%, 
thrombotic Discharged 
20 70 F 26.6 Y Y N N N N N N Y N I 150 85 92 ST-elevation, inferolateral 55 4,5,10,11,15  prox LCX 
100%, 
thrombotic Discharged 
21 57 M 26.4 Y Y N N Y N N N Y N I 110 62 98 ST-elevation, inferior 57 4,10,15 prox LCX 
100%, 
thrombotic Discharged 
22 67 M 24.2 N N N N N N N N Y N I 140 80 98 ST-elevation, inferior 55 4,10,15 prox RCA 
100%, 
thrombotic Discharged 
23 58 M 34.5 Y Y Y N N N N N Y Y IV 140 95 97 ST-elevation, inferior 45 4,10,15 prox RCA 
100%, 
thrombotic ICU 
24 74 M 27.3 Y Y Y - N Y N N Y N IV 80 98 86 ST-elevation, inferolateral 30 4,10,15 mid RCA 
99%, 
thrombotic Death 
25 83 M 25.4 Y Y Y Y N Y N Y Y Y I 130 75 99 ST-elevation, inferolateral 38 4,10,15 mid RCA 
100%, 
thrombotic Discharged 
26 61 M 21.7 Y Y Y N Y N Y N Y N I 160 68 97 ST-elevation, inferior 54 4,5 mid RCA 
100%, 
thrombotic Discharged 
27 72 M 21.6 N N N N N N N N Y Y IV 60 42 90 ST-elevation, inferior 20 Diffuse mid RCA 
100%, 
thrombotic Death 
28 74 F 22.5 Y N N N N N N N N Y IV 100 66 98 ST-elevation, inferior 35 3,4,5,9,10,11 PDA 
100%, 
thrombotic Death 
BMI=body mass index, bpm=beats per minute, CKD=chronic kidney disease, Dyslip=dyslipidemia, DM=diabetes mellitus, EKG=electrocardiographic, F=female, HTN= arterial hypertension, HR=heart rate, ICU=intensive care unit, LAD=left anterior descending, LBBB=left bundle branch block, LCX=left circumflex artery, LM=left main, 
LVEF=left ventricular ejection fraction, M=male, MI=myocardial infarction, PCI=percutaneous coronary interventions, PDA=posterior descending artery, N=no, O2 sat=oxygen saturation, RCA=right coronary artery, SBP=systolic blood pressure, WMA=Wall motion abnormalities assessed by echocardiography, segments based on the cardiac 
segmentation model of the American Heart Association (AHA).  Y=yes. *As of March 31, 2020 (median follow-up 13 days, interquartile range 2-20 days).BMI=body mass index, bpm=beats per minute, CKD=chronic kidney disease, Dyslip=dyslipidemia, DM=diabetes mellitus, EKG=electrocardiographic, F=female, HTN= arterial hypertension, 
HR=heart rate, ICU=intensive care unit, LAD=left anterior descending, LBBB=left bundle branch block, LCX=left circumflex artery, LM=left main, LVEF=left ventricular ejection fraction, M=male, MI=myocardial infarction, PCI=percutaneous coronary interventions, PDA=posterior descending artery, N=no, O2 sat=oxygen saturation, RCA=right 
coronary artery, SBP=systolic blood pressure, WMA=Wall motion abnormalities assessed by echocardiography, segments based on the cardiac segmentation model of the American Heart Association (AHA).  Y=yes. *As of March 31, 2020 (median follow-up 13 days, interquartile range 2-20 days).  
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